Advocacy intelligence hub — real-time data for patient organizations
Bursa City Hospital
University of Colorado, Denver — NA
Kangbuk Samsung Hospital — NA
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization — NA
Sixth Affiliated Hospital, Sun Yat-sen University — NA
Cairo University
Shenyang Medical College — NA
Istanbul University
University of Washington — PHASE4
Swedish Orphan Biovitrum — PHASE4
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
ILARIS
(canakinumab)Orphan drugNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutr...
Colcrys
(colchicine)Orphan drugAR Holding Company, Inc.
Alkaloid [EPC]
12.1 Mechanism of Action The mechanism by which COLCRYS exerts its beneficial effect in patients with FMF has not been fully elucidated; however, evid...
Yves DAUVILLIERS, MD PhD
University Hospital, Montpellier
Yan Li, PhD
Oregon Health and Science University
Fereydoun Davatchi, MD
Rheumatology Research Center, Tehran University for Medical Sciences
Farhad Shahram, MD
Rheumatology Research Center, Tehran University for Medical Sciences
Shunsei Hirohata, MD
Kitasato University School of Medicine
Use Central Contact
Astellas Pharma Inc